Clinuvel Pharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Key Metrics
PE ratio
12.18
PB ratio
1.51
Dividend yield
0.61%
Beta
0.56
Market cap
$411.49M
Enterprise value
$161.37M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.clinuvel.com |
| Mailing address | 535 Bourke Street Level 22 Melbourne VIC 3000 Australia |
| Phone / Fax | 61 3 9660 4900 / 61 3 9660 4999 |
Dividends
More: Clinuvel Pharmaceuticals Dividend history, yield and payout ratio
Dividend yield
0.61%
Dividend amount
$0.05
Payout ratio
7.49%
5Y Avg. yield
-%
Clinuvel Pharmaceuticals paid $0.05 dividend and the ex-dividend date was 03 Sep 2026.The dividend payout ratio is 7.49%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.CUV dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Sep 2026, following are the company executives and directors listed on Clinuvel Pharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Philippe Jacques Wolgen M.B.A., M.D. | CEO, MD & Director | 62 | |
| Mr. Peter Vaughan | Chief Financial Officer | ||
| Mr. Lachlan Hay | Chief Operations Officer | ||
| Dr. Dennis J. Wright BPharm, M.Sc., Ph.D. | Chief Scientific Officer | ||
| Mr. Malcolm Bull | Head of Australian Operations & Investor Relations | ||
| Dr. Azza Hamila | Head of Quality Assurance & Drug Safety | ||
| Ms. Claire Newstead-Sinclair C.A. | Company Secretary | ||
| Dr. Linda Teng | Director of North American Operations | ||
| Dr. Emilie Rodenburger | Director of Global Clinical Affairs |
Profitability and management effectiveness
Profit margin
36.07%
Operating margin
47.32%
Return on assets
8.94%
Return on equity
13.21%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Clinuvel Pharmaceuticals is 411.49M and its enterprise value is 161.37M. The enterprise value to revenue ratio of CUV is 1.72. The enterprise value to EBITDA ratio of CUV is 3.93.
The CUV's stocks Beta value is 0.56 making it 44% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Clinuvel Pharmaceuticals (CUV)
Clinuvel Pharmaceuticals (ASX:CUV) Frequently Asked Questions
1. What is Clinuvel Pharmaceuticals's Stock Symbol?
Clinuvel Pharmaceuticals trades on ASX under the ticker symbol "CUV".
2. What is Clinuvel Pharmaceuticals's stock price today?
One share of CUV stock can currently be purchased for approximately $8.16.
3. How can I contact Clinuvel Pharmaceuticals?
Clinuvel Pharmaceuticals's mailing address is 535 Bourke Street Level 22 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9660 4900.
4. What is Clinuvel Pharmaceuticals's official website?
The official website of Clinuvel Pharmaceuticals is https://www.clinuvel.com.